{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T03:15:12Z","timestamp":1766546112396,"version":"3.44.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.jns.2015.07.031","type":"journal-article","created":{"date-parts":[[2015,7,23]],"date-time":"2015-07-23T01:46:30Z","timestamp":1437615990000},"page":"204-208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Impact of dabigatran on platelet function and fibrinolysis"],"prefix":"10.1016","volume":"357","author":[{"given":"Argirios E.","family":"Tsantes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias","family":"Kyriakou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanos","family":"Bonovas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Chondrogianni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Zompola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chrissoula","family":"Liantinioti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athina","family":"Simitsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aristeidis H.","family":"Katsanos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Atta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignatios","family":"Ikonomidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Violetta","family":"Kapsimali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petros","family":"Kopterides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Tsivgoulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2015.07.031_bb0005","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2015.07.031_bb0010","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Conolly","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2015.07.031_bb0015","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2015.07.031_bb0020","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2125.2007.02899.x","article-title":"The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects","volume":"64","author":"Stangier","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jns.2015.07.031_bb0025","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/jth.12096","article-title":"Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants","volume":"11","author":"Garcia","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.jns.2015.07.031_bb0030","doi-asserted-by":"crossref","DOI":"10.1111\/jth.12149","article-title":"Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis","author":"Baglin","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.jns.2015.07.031_bb0035","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1177\/1076029614564209","article-title":"Laboratory assessment of the anticoagulant activity of dabigatran","volume":"21","author":"Kyriakou","year":"2015","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"10.1016\/j.jns.2015.07.031_bb0040","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1160\/TH10-02-0097","article-title":"Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin","volume":"104","author":"Wong","year":"2010","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.jns.2015.07.031_bb0045","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1515\/cclm-2013-0936","article-title":"Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests","volume":"52","author":"Eller","year":"2014","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.jns.2015.07.031_bb0050","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/1756285614528064","article-title":"Dabigatran etexilate for secondary stroke prevention: the first year experience from a multicenter short-term registry","volume":"7","author":"Tsivgoulis","year":"2014","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.jns.2015.07.031_bb0055","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/MBC.0b013e32834f1b0c","article-title":"Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran","volume":"23","author":"Stangier","year":"2012","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.jns.2015.07.031_bb0060","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1111\/j.1476-5381.2011.01668.x","article-title":"Antiplatelet and antithrombotic effect of F 16618, a new thrombin proteinase-activated receptor-1 (PAR1) antagonist","volume":"165","author":"Dumas","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jns.2015.07.031_bb0065","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-2007-995840","article-title":"PFA-100 system: a new method for assessment of platelet dysfunction","volume":"24","author":"Mammen","year":"1998","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.jns.2015.07.031_bb0070","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1365-2257.2002.00451.x","article-title":"The PFA-100: a potential rapid screening tool for the assessment of platelet dysfunction","volume":"24","author":"Harrison","year":"2002","journal-title":"Clin. Lab. Haematol."},{"key":"10.1016\/j.jns.2015.07.031_bb0075","first-page":"136","article-title":"When 100% really isn't 100%: improving the accuracy of small-sample estimates of completion rates","volume":"1","author":"Lewis","year":"2006","journal-title":"J. Usability Stud."},{"key":"10.1016\/j.jns.2015.07.031_bb0080","first-page":"280","article-title":"Thrombin facilitates primary platelet adhesion onto vascular surfaces in the absence of plasma adhesive proteins: studies under flow conditions","volume":"85","author":"Diaz-Ricart","year":"2000","journal-title":"Haematologica"},{"key":"10.1016\/j.jns.2015.07.031_bb0085","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/35092573","article-title":"Role of thrombin signalling in platelets in haemostasis and thrombosis","volume":"413","author":"Sambrano","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.jns.2015.07.031_bb0090","doi-asserted-by":"crossref","first-page":"717","DOI":"10.5301\/ijao.5000239","article-title":"Platelet-related hemostasis before and after hemodialysis with five different anticoagulation methods","volume":"36","author":"Knehtl","year":"2013","journal-title":"Int. J. Artif. Organs"},{"key":"10.1016\/j.jns.2015.07.031_bb0095","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/ndt\/gft209","article-title":"Haemostasis in chronic kidney disease","volume":"29","author":"Lutz","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.jns.2015.07.031_bb0100","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1172\/JCI118315","article-title":"Plasma carboxypeptidases as regulators of the plasminogen system","volume":"96","author":"Redlitz","year":"1995","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jns.2015.07.031_bb0105","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMc1111095","article-title":"Acutely injured patients on dabigatran","volume":"365","author":"Cotton","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2015.07.031_bb0110","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/j.jacc.2013.03.020","article-title":"Efficacy and safety of dabigatran etexilate and warfarin in \u201creal world\u201d patients with atrial fibrillation: a prospective nationwide cohort study","volume":"61","author":"Larsen","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.jns.2015.07.031_bb0115","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jacc.2013.05.066","article-title":"Dabigatran's \u201creal-world\u201d data about risk of myocardial infarction and gastrointestinal bleeding contradicts with randomized trials","volume":"62","author":"Sipahi","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.jns.2015.07.031_bb0120","doi-asserted-by":"crossref","first-page":"g4681","DOI":"10.1136\/bmj.g4681","article-title":"The trouble with dabigatran","volume":"349","author":"Charlton","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.jns.2015.07.031_bb0125","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2013.07.104","article-title":"The effects of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients","volume":"63","author":"Reilly","year":"2014","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X15004529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X15004529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:44:24Z","timestamp":1758383064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X15004529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":25,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0022510X15004529"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2015.07.031","relation":{},"ISSN":["0022-510X"],"issn-type":[{"type":"print","value":"0022-510X"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of dabigatran on platelet function and fibrinolysis","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2015.07.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}